We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay

By LabMedica International staff writers
Posted on 22 Jan 2024
Print article
Image: The Mispa i4 fully automated cartridge based specific protein analyzer and clinical chemistry analyzer (Photo courtesy of Agappe)
Image: The Mispa i4 fully automated cartridge based specific protein analyzer and clinical chemistry analyzer (Photo courtesy of Agappe)

Fujirebio Holdings (Tokyo, Japan) and Agappe Diagnostics (Kochi, India) have entered into a Contract Development and Manufacturing Organization (CDMO) partnership for manufacturing cartridge-based CLIA system reagents for the Mispa i60 and Mispa i121 immunology analyzers. These analyzers and reagents will be sold under Agappe’s brand, making it the first Indian local company with a complete chemiluminescence solution made from reagents produced domestically.

The companies have outlined plans to launch these products in June 2024. Significant milestones have already been achieved, including the finalization of a supply and license agreement in March 2023. Agappe is currently in the advanced stages of technical transfer from Fujirebio, which will enable the Indian company to manufacture chemiluminescence reagents using Fujirebio’s technology and materials. The collaboration is set to make a substantial impact, with phased launches planned for a complete range of over 30 parameters, spanning various medical segments such as oncology, thyroid, cardiac, fertility, and infectious diseases. Additionally, Fujirebio’s groundbreaking biomarkers for Alzheimer’s and other neurodegenerative diseases are also included in this project.

Under this agreement, Fujirebio will be responsible for supplying the Mispa i60 and i121 analyzers and the raw materials for the reagents. Agappe, on the other hand, will focus on developing and manufacturing reagents specifically tailored for these instruments, ensuring compliance with all regulatory requirements. This partnership is based on a shared vision of leveraging each company’s unique strengths to not only foster growth in India's immunoassay market but also to significantly contribute to the advancement and enhancement of immunoassay solutions within the Indian healthcare sector.

“This partnership with Agappe, the renowned market leader with years of success in clinical chemistry, hematology, immunochemistry, and point of care in India, will accelerate our CDMO strategy in one of the most important and fastest growing countries in the world,” said Goki Ishikawa, President and CEO, Fujirebio Holdings, Inc. “We share a vision that, combining mutually complementary strengths of both companies, Agappe together with Fujirebio can deliver high-quality chemiluminescence solutions with cost competitiveness and contribute to the healthcare advancement in India.”

“Leveraging the combined strengths of Agappe and Fujirebio, we are committed to introducing high quality, affordable, and unique chemiluminescence solutions for the country,” added Thomas John, Managing Director, Agappe Diagnostics, Ltd. “This partnership symbolizes our dedication to innovation and our pledge to make advanced diagnostic products more accessible to every Indian. We are poised to set new benchmarks in the industry, emphasizing our joint endeavor to enhance healthcare standards across our nation."

Related Links:
Fujirebio Holdings 
Agappe Diagnostics

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.